Thermo Fisher Scientific (TMO) Capital Expenditures (2009 - 2026)

Thermo Fisher Scientific has disclosed Capital Expenditures across 18 years of filings, most recently posting $376.0 million for Q1 2026.

• Quarterly Capital Expenditures rose 3.87% year-over-year to $376.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 8.76% YoY) and the FY2025 annual result came in at $1.5 billion, up 8.93% from the prior year.
• Capital Expenditures fell to $376.0 million in Q1 2026, from $465.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $640.0 million in Q2 2022 and troughed at $272.0 million in Q3 2024.
• A 5-year average of $413.1 million and a median of $404.0 million in 2025 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2023 — Capital Expenditures plunged 43.87% — and 2025, when it jumped 48.53%.
• Tracing TMO's Capital Expenditures over 5 years: stood at $550.0 million in 2022, then slipped by 26.36% to $405.0 million in 2023, then increased by 18.52% to $480.0 million in 2024, then declined by 3.12% to $465.0 million in 2025, then slipped by 19.14% to $376.0 million in 2026.
• Business Quant data shows TMO's Capital Expenditures at $376.0 million in Q1 2026, $465.0 million in Q4 2025, and $404.0 million in Q3 2025.